Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Interleukin (IL)-17 is a proinflammatory and fibrogenic cytokine mainly produced by T-helper (Th)17 lymphocytes, together with the hepatoprotective and antifibrogenic cytokine, IL-22. Cannabinoid receptor 2 (CB2) is predominantly expressed in immune cells and displays anti-inflammatory and antifibrogenic effects. In the present study, we further investigated the mechanism underlying antifibrogenic properties of CB2 receptor and explored its effect on the profibrogenic properties of IL-17. After bile duct ligation (BDL), the hepatic expression of Th17 markers and IL-17 production were enhanced in CB2−/− mice, as compared to wild-type (WT) counterparts, and correlated with increased fibrosis in these animals. In contrast, IL-22-induced expression was similar in both animal groups. Inhibition of Th17 differentiation by digoxin lowered Th17 marker gene expression and IL-17 production and strongly reduced liver fibrosis in CB2−/− BDL mice. In vitro , differentiation of CD4+ naïve T cells into Th17 lymphocytes was decreased by the CB2 agonist, JWH-133, and was associated with reduced Th17 marker messenger RNA expression and IL-17 production, without modification of IL-22 release. The inhibitory effect of JWH-133 on IL-17 production relied on signal transducer and activator of transcription (STAT)5 phosphorylation. Indeed, STAT5 phosphorylation and translocation into the nucleus was enhanced in JWH133-treated Th17 lymphocytes, and the addition of a STAT5 inhibitor reversed the inhibitory effect of the CB2 agonist on IL-17 production, without affecting IL-22 levels. Finally, in vitro studies also demonstrated that CB2 receptor activation in macrophages and hepatic myofibroblasts blunts IL-17-induced proinflammatory gene expression. Conclusion : These data demonstrate that CB2 receptor activation decreases liver fibrosis by selectively reducing IL-17 production by Th17 lymphocytes via a STAT5-dependent pathway, and by blunting the proinflammatory effects of IL-17 on its target cells, while preserving IL-22 production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
TH17 cells in development: an updated view of their molecular identity and genetic programming
Dong, C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2295 · Cited by 1,064 · cited 3×
“A predominant Th1 response, characterized by a high production of type 2 interferon-gamma (IFN-c), results in the inhibition of liver fibrosis subsequent to MFB apoptosis.4,5 In contrast, Th2 polarization promotes liver fibrosis, in particular, by production of interleukin (IL)213.6 Though the Th1/Th2 paradigm galvani…”
BackgroundInfluentialBleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730 · cited 1×
“These data are in line with recent studies describing the profibrogenic properties of IL-17 in different experimental models of liver, pulmonary, or myocardial fibrosis by direct effects on myofibroblasts or indirectly by release of proinflammatory and fibrogenic cytokines from macrophages.(10,13,14,32) Interestingly,…”
ResultCannabinoid-based drugs as anti-inflammatory therapeutics
Klein, T. W. (2005) · Nature Reviews Immunology · doi:10.1038/nri1602 · Cited by 728 · cited 1×
“CB2 receptor is abundantly expressed in immune cells, including natural killer (NK), NKT, B, and T lymphocytes as well as monocytes and macrophages and generally displays potent anti-inflammatory properties.(18) In the liver, CB2 receptor is induced after an acute or chronic injury, in both immune and liver fibrogenic…”
BackgroundMeng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 5×
“These data are in line with recent studies describing the profibrogenic properties of IL-17 in different experimental models of liver, pulmonary, or myocardial fibrosis by direct effects on myofibroblasts or indirectly by release of proinflammatory and fibrogenic cytokines from macrophages.(10,13,14,32) Interestingly,…”
BackgroundResultInfluentialDigoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809763105 · Cited by 624 · cited 1×
“Hypoxia-inducible factor (HIF)21a is a transcriptional factor involved in BDL-induced liver fibrosis,(28) and its expression is down-regulated in digoxin-treated Hep3B cells.(29) Therefore, we wondered whether antifibrotic effects of digoxin could be mediated through inhibition of Hif1a in Th17 cells.”
BackgroundYang, X.-P., Ghoreschi, K., Steward-Tharp, S. M., Rodriguez-Canales, J., Zhu, J., Grainger, J. R., Hirahara, K., Sun, H.-W., Wei, L., Vahedi, G., et al. (2011) · Nature Immunology · doi:10.1038/ni.1995 · Cited by 583 · cited 2×
“Interestingly, recent studies have shown that STAT5 restrains STAT3-induced IL-17 gene expression by competing for the same binding sites in the IL-17 promoter.(30) Our data show that CB2 receptor activation by JWH-133 promotes STAT5 phosphorylation and its translocation within Th17 nuclei, suggesting that STAT5 could…”
BackgroundInterleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice
Kong, X., Feng, D., Wang, H., Hong, F., Bertola, A., Wang, F.-S., & Gao, B. (2012) · Hepatology · doi:10.1002/hep.25744 · Cited by 448
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
The interleukin-17 pathway is involved in human alcoholic liver disease # †
Lemmers, A., Moreno, C., Gustot, T., Maréchal, R., Degré, D., Demetter, P., de Nadai, P., Geerts, A., Quertinmont, E., Vercruysse, V., et al. (2009) · Hepatology · doi:10.1002/hep.22680 · Cited by 394 · cited 9×
“These data are in line with our previous study24 and further argue for a major role of CB2 receptor as a regulator of the KC M1/M2 balance.24 In addition, JWH-133 strongly reduced the proinflammatory response elicited by IL-17 in MFBs.”
BackgroundResultInfluentialHepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325 · cited 6×
“These data are in line with our previous study24 and further argue for a major role of CB2 receptor as a regulator of the KC M1/M2 balance.24 In addition, JWH-133 strongly reduced the proinflammatory response elicited by IL-17 in MFBs.”
BackgroundInfluentialSelf-citationCencioni, M. T., Chiurchiù, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., & Maccarrone, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008688 · Cited by 235 · cited 1×
“Recent data have shown immunosuppressive properties of CB2 receptor on Th17 cells.(25) In the present study, we therefore explored whether inhibition of IL-17 response may contribute to the antifibrogenic effects of CB2 receptors in the liver.”
BackgroundFeng, W., Li, W., Liu, W., Wang, F., Li, Y., & Yan, W. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.06.001 · Cited by 139
The liver X receptor in hepatic stellate cells: a novel antifibrogenic target?
Mallat, A., & Lotersztajn, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.05.018 · Cited by 11
Self-citation
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
“In contrast, CB2 signaling has the opposite effect on stellate cells and can also antagonize profibrotic signaling by TH17 lymphocytes (Guillot et al., 2014).”
BackgroundHepatic stellate cells as key target in liver fibrosis
Higashi, T., Friedman, S. L., & Hoshida, Y. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.007 · Cited by 1,485
Immunology in the liver — from homeostasis to disease
Heymann, F., & Tacke, F. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.200 · Cited by 1,180
Endocannabinoid signaling at the periphery: 50 years after THC
Maccarrone, M., Bab, I., Bíró, T., Cabral, G. A., Dey, S. K., Di Marzo, V., Konje, J. C., Kunos, G., Mechoulam, R., Pacher, P., et al. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.008 · Cited by 646
Metadata
- Authors
- Guillot, A., Hamdaoui, N., Bizy, A., Zoltani, K., Souktani, R., Zafrani, E.-S., Mallat, A., Lotersztajn, S., & Lafdil, F.
- Venue
- Hepatology
- Published
- 2014-01
- Volume
- 59
- Issue
- 1
- Pages
- 296-306
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2133052414
- Cited by
- 127
- References
- 14
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.